Recently, 15 companies from BioBAY, a biotech cluster in SIP, participated in the AACR (American Association for Cancer Research) Annual Meeting 2025 with 42 breakthrough research outcomes.
About 42% of the outcomes are antibody-drug conjugates (ADCs) which combine targeted therapy and chemotherapy to enable targeted delivery of cytotoxic agents to tumor site through recognizing target antigens by antibody while minimizing off-target effects on healthy tissues.
The achievements that the SIP-based companies have made, such as the YL217 developed by MediLink Therapeutics for treatment of gastrointestinal tumors and the BG-C137 (a FGFR2b ADC) developed by BeiGene, attracted wide attention at the event.
Moreover, the companies also showcased stunning technological diversity and strong innovation ability.
May 14, 2025
